PolyPid (PYPD) Preferred Stock Liabilities (2019 - 2020)
PolyPid (PYPD) posted Preferred Stock Liabilities of $106.3 million for Q4 2020, little changed sequentially from $106.3 million in Q4 2019, and little changed YoY from $106.3 million in Q1 2020.
PolyPid (PYPD) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
PolyPid has reported Preferred Stock Liabilities for 2 years, with the latest figure at $106.3 million in Q4 2020.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $106.3 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $106.3 million (changed 0.0% YoY) and the FY2020 annual result came in at $106.3 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $106.3 million in Q4 2020 per PYPD's latest filing, from $106.3 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $106.3 million in Q4 2019 and troughed at $106.3 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 106.31 Mn |
| Dec 31, 2019 | 106.31 Mn |